riluzole has been researched along with Spondylosis in 4 studies
Riluzole: A glutamate antagonist (RECEPTORS, GLUTAMATE) used as an anticonvulsant (ANTICONVULSANTS) and to prolong the survival of patients with AMYOTROPHIC LATERAL SCLEROSIS.
Spondylosis: A degenerative spinal disease that can involve any part of the VERTEBRA, the INTERVERTEBRAL DISK, and the surrounding soft tissue.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Riluzole treatment attenuated oxidative DNA damage in the spinal cord and postoperative decline after decompression surgery." | 6.80 | Riluzole blocks perioperative ischemia-reperfusion injury and enhances postdecompression outcomes in cervical spondylotic myelopathy. ( Arnold, P; Chung, YS; Fehlings, MG; Foltz, WD; Karadimas, SK; Laliberte, AM; Tetreault, L, 2015) |
| "Cervical spondylotic myelopathy (CSM) is the commonest cause of spinal cord impairment worldwide and despite surgical treatment, it is commonly associated with chronic neuropathic pain and neurological impairment." | 5.40 | Riluzole attenuates neuropathic pain and enhances functional recovery in a rodent model of cervical spondylotic myelopathy. ( Austin, JW; Fehlings, MG; Karadimas, SK; Moon, ES; Yu, WR, 2014) |
| "To explain the rationale and design of the cervical spondylotic myelopathy (CSM)-Protect clinical trial that aims to elucidate the efficacy and safety of riluzole in the context of CSM." | 4.89 | Clinical evaluation of a neuroprotective drug in patients with cervical spondylotic myelopathy undergoing surgical treatment: design and rationale for the CSM-Protect trial. ( Arnold, PM; Fehlings, MG; Karadimas, SK; Kopjar, B; Wilson, JR, 2013) |
| "Riluzole treatment attenuated oxidative DNA damage in the spinal cord and postoperative decline after decompression surgery." | 2.80 | Riluzole blocks perioperative ischemia-reperfusion injury and enhances postdecompression outcomes in cervical spondylotic myelopathy. ( Arnold, P; Chung, YS; Fehlings, MG; Foltz, WD; Karadimas, SK; Laliberte, AM; Tetreault, L, 2015) |
| "Cervical spondylotic myelopathy (CSM) is the commonest cause of spinal cord impairment worldwide and despite surgical treatment, it is commonly associated with chronic neuropathic pain and neurological impairment." | 1.40 | Riluzole attenuates neuropathic pain and enhances functional recovery in a rodent model of cervical spondylotic myelopathy. ( Austin, JW; Fehlings, MG; Karadimas, SK; Moon, ES; Yu, WR, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Moghaddamjou, A | 1 |
| Badhiwala, JH | 1 |
| Fehlings, MG | 4 |
| Wilson, JR | 1 |
| Karadimas, SK | 3 |
| Arnold, PM | 1 |
| Kopjar, B | 1 |
| Moon, ES | 1 |
| Yu, WR | 1 |
| Austin, JW | 1 |
| Laliberte, AM | 1 |
| Tetreault, L | 1 |
| Chung, YS | 1 |
| Arnold, P | 1 |
| Foltz, WD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy of Riluzole in Patients With Cervical Spondylotic Myelopathy Undergoing Surgical Treatment. A Randomized, Double-Blind, Placebo-controlled Multi-Center Study[NCT01257828] | Phase 3 | 270 participants (Actual) | Interventional | 2012-03-31 | Completed | ||
| Regeneration in Cervical Degenerative Myelopathy - a Multi-centre, Double-blind, Randomised, Placebo Controlled Trial Assessing the Efficacy of Ibudilast as an Adjuvant Treatment to Decompressive Surgery for Degenerative Cervical Myelopathy[NCT04631471] | Phase 3 | 400 participants (Anticipated) | Interventional | 2021-12-22 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for riluzole and Spondylosis
1 trial available for riluzole and Spondylosis
| Article | Year |
|---|---|
Riluzole blocks perioperative ischemia-reperfusion injury and enhances postdecompression outcomes in cervical spondylotic myelopathy.
Topics: Animals; Axons; Cervical Vertebrae; Decompression, Surgical; Disease Models, Animal; Humans; Magneti | 2015 |
2 other studies available for riluzole and Spondylosis
| Article | Year |
|---|---|
Degenerative Cervical Myelopathy: Changing Frontiers.
Topics: Cell- and Tissue-Based Therapy; Cervical Vertebrae; Excitatory Amino Acid Antagonists; Genetic Thera | 2020 |
Riluzole attenuates neuropathic pain and enhances functional recovery in a rodent model of cervical spondylotic myelopathy.
Topics: Animals; Disease Models, Animal; Excitatory Amino Acid Antagonists; Female; Gait; Hyperalgesia; Neur | 2014 |